October 13, 2026
Regina Hodits shares how Angelini Ventures targets rare diseases and why Europe must expand institutional capital across VC stages.
September 28, 2026
MedinCell CEO Christophe Douat on disrupting psychiatric care with long-acting injectables, achieving a $1B+ valuation, and their 20-year journey.
July 6, 2026
Billionaire Christian Angermayer on GLP-1s, psychedelics, and the untapped, multi-billion dollar market of consumer biotech.
June 8, 2026
ImCheck's ex-CEO on the $1.2B exit to Ibsen, key ASCO oncology trends like ADCs, and critical lessons for biotech founders on fundraising.
June 1, 2026
PathoQuest CEO Jean-François Brepson on scaling a CRO with NGS tech, US expansion, and the strategic acquisition by Charles River.
May 25, 2026
Ex-Incyte CEO Hervé Hoppenot on scaling 10x, navigating biotech cycles, trusting biology over forecasts, and why bureaucracy is a choice.
May 11, 2026
Christoph Lengauer of Curie.Bio discusses their founder-centric VC model, offering deep operational support and higher equity for biotech founders.
April 13, 2026
Forbion's Sander Slootweg on closing Europe's biotech funding gap, pioneering Asian asset in-licensing, and building a resilient VC ecosystem.
April 8, 2026
Immunethep tackles the AMR crisis with a novel vaccine targeting bacterial immune evasion, offering a broad-spectrum solution beyond antibiotics.
February 16, 2026
Novonesis CSO Claus Fuglsang on leading the biosolutions revolution through its $12B merger, a powerful R&D engine, and customer-centricity.
February 9, 2026
Cereno Scientific's CEO on repurposing an old drug for PAH, detailing positive Phase 2a data, a multi-layered IP strategy, and a large retail investor base.
January 12, 2026
Transgene's CEO discusses next-gen cancer vaccines, individualized therapies, and their recent €105M fundraising to advance their platforms.
January 6, 2026
Biotech veteran Pascal Touchon on the cell therapy evolution, from Kymriah to in vivo CAR-T, and JTO's data-driven investment strategy.